Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway concept.
Alb M, Reiche K, Rade M, Sewald K, Loskill P, Cipriano M, Maulana TI, van der Meer AD, Weener HJ, Clerbaux LA, Fogal B, Patel N, Adkins K, Lund E, Perkins E, Cooper C, van den Brulle J, Morgan H, Rubic-Schneider T, Ling H, DiPetrillo K, Moggs J, Köhl U, Hudecek M. Alb M, et al. Among authors: hudecek m. J Immunotoxicol. 2024 Oct;21(sup1):S13-S28. doi: 10.1080/1547691X.2024.2345158. Epub 2024 Dec 10. J Immunotoxicol. 2024. PMID: 39655500 Free article. Review.
Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells.
Maulana TI, Teufel C, Cipriano M, Roosz J, Lazarevski L, van den Hil FE, Scheller L, Orlova V, Koch A, Hudecek M, Alb M, Loskill P. Maulana TI, et al. Among authors: hudecek m. Cell Stem Cell. 2024 Jul 5;31(7):989-1002.e9. doi: 10.1016/j.stem.2024.04.018. Epub 2024 May 15. Cell Stem Cell. 2024. PMID: 38754430 Free article.
Immunocompetent cancer-on-chip models to assess immuno-oncology therapy.
Maulana TI, Kromidas E, Wallstabe L, Cipriano M, Alb M, Zaupa C, Hudecek M, Fogal B, Loskill P. Maulana TI, et al. Among authors: hudecek m. Adv Drug Deliv Rev. 2021 Jun;173:281-305. doi: 10.1016/j.addr.2021.03.015. Epub 2021 Mar 30. Adv Drug Deliv Rev. 2021. PMID: 33798643 Free article. Review.
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models.
Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, De Angelis B, Choudhary R, Espie D, Galy A, Holland C, Ivics Z, Kantari-Mimoun C, Kersten MJ, Köhl U, Kuhn C, Laugel B, Locatelli F, Marchiq I, Markman J, Moresco MA, Morris E, Negre H, Quintarelli C, Rade M, Reiche K, Renner M, Ruggiero E, Sanges C, Stauss H, Themeli M, Van den Brulle J, Hudecek M, Casucci M. Donnadieu E, et al. Among authors: hudecek m. J Immunother Cancer. 2022 May;10(5):e003486. doi: 10.1136/jitc-2021-003486. J Immunother Cancer. 2022. PMID: 35577500 Free PMC article. Review.
Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?
Guedan S, Luu M, Ammar D, Barbao P, Bonini C, Bousso P, Buchholz CJ, Casucci M, De Angelis B, Donnadieu E, Espie D, Greco B, Groen R, Huppa JB, Kantari-Mimoun C, Laugel B, Mantock M, Markman JL, Morris E, Quintarelli C, Rade M, Reiche K, Rodriguez-Garcia A, Rodriguez-Madoz JR, Ruggiero E, Themeli M, Hudecek M, Marchiq I. Guedan S, et al. Among authors: hudecek m. J Immunother Cancer. 2022 May;10(5):e003487. doi: 10.1136/jitc-2021-003487. J Immunother Cancer. 2022. PMID: 35577501 Free PMC article. Review.
Teclistamab impairs detection of BCMA CAR-T cells.
Glatte B, Wenk K, Grahnert A, Friedrich M, Merz M, Vucinic V, Fischer L, Reiche K, Alb M, Hudecek M, Franz P, Fricke S, Platzbecker U, Koehl U, Sack U, Boldt A, Hauschildt S, Weiss R. Glatte B, et al. Among authors: hudecek m. Blood Adv. 2023 Aug 8;7(15):3842-3845. doi: 10.1182/bloodadvances.2023009714. Blood Adv. 2023. PMID: 37026812 Free PMC article. No abstract available.
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).
Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, Corbacioglu S, Duarte RF, Einsele H, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Robinson S, Saccardi R, Sanchez-Guijo F, Snowden JA, Srour M, Styczynski J, Urbano-Ispizua A, Hayden PJ, Kröger N. Yakoub-Agha I, et al. Among authors: hudecek m. Haematologica. 2020 Jan 31;105(2):297-316. doi: 10.3324/haematol.2019.229781. Print 2020. Haematologica. 2020. PMID: 31753925 Free PMC article.
Cellular Therapies for Multiple Myeloma: Engineering Hope.
Vera-Cruz S, Jornet Culubret M, Konetzki V, Alb M, Friedel SR, Hudecek M, Einsele H, Danhof S, Scheller L. Vera-Cruz S, et al. Among authors: hudecek m. Cancers (Basel). 2024 Nov 19;16(22):3867. doi: 10.3390/cancers16223867. Cancers (Basel). 2024. PMID: 39594822 Free PMC article. Review.
128 results